来那度胺治疗难治复发慢性淋巴细胞白血病疗效及不良反应的meta分析

doi:doi:10.3969/j.issn.1672-3384.2017.01.005

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (987 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：评价来那度胺（L）±CD20 单抗治疗难治复发慢性淋巴细胞白血病（CLL）的疗效和不良反应。方法：计算机检索PubMed/Medline，Embase，中国期刊网数据库（CNKI）、万方数据库（VIP）、维普网，中国生物医学文献数据库（CBM），以及ClinicalTrials.gov、美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）网站，对纳入的文献进行治疗评价并提取相关数据。采用R 软件对提取数据进行Meta 分析，计算有效率、不良反应发生率、相对风险率（RRR）和95% 置信区间（95% CI）。结果：共纳入17 个队列研究进行后续分析。结果显示，来那度胺治疗的总有效率（完全缓解+ 部分缓解）为42.10%（95%CI ：32.41%~52.43%，I 2=79.1%），采用L+CD20 单抗治疗方案的有效率为60.01%（95% CI ：53.88%~65.86%），而采用L 单药治疗方案的有效率为24.31% （95% CI ：16.34%~34.67%）。3~4 级中性粒细胞减少为来那度胺最常见的不良反应，发生率为61.98%（95% CI ： 54.01%~69.35%）。3~4 级血小板减少和血红蛋白降低的发生率分别为21.33%（95% CI：14.15%~30.84%）和11.32%（95% CI：8.46%~14.98%）。3~4 级感染事件的发生率为33.52% (95% CI：28.99%~38.38%)。其他报道较多的不良反应包括“燃瘤作用”，静脉血栓和疲劳等。结论：在难治复发CLL 的治疗中，对于欧美外无法获得新药国家的患者及对此类新药耐药的患者，含有来那度胺的方案也许是有效的治疗手段。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	梁良
	赵明
	朱愿超
	胡欣
	杨莉萍

关键词 ：慢性淋巴细胞白血病, 难治复发, 来那度胺, 不良反应, meta 分析

Abstract：Objective: Efficacy and adverse effect of lenalidomide monotherapy or in combination with anti-CD20 monoclonal antibody (mAbs) in relapsed/refractory chronic lymphocytic leukemia was evaluated. Methods: We conducted a literature search using the PubMed/Medline and Embase database, as well as Chinese language databases, including the Chinese Biomedical Literature Database, and Wanfang. We also searched the Cochrane Library for any recent systematic review on the subject, the ClinicalTrials.gov database, the websites of European Medicines Agency (EMA) and US Food and Drug Administration (FDA). R software and was used for all statistical analyses. Results: 17 cohort studies were included in the final analyses. Pooled estimates of cumulative prevalence of total ORR was 42.10% (95%CI :32.41%-52.43%). The pooled ORR in regimen with lenalidomide plus anti-CD20 antibody and lenalidomide mono-therapy are 60.01% (95% CI , :53.86%-65.86%) and 24.31%(95% CI :16.34%-34.67%) respectively.Cumulative prevalence of neutropenia was 61.98%(95% CI , 54.01%-69.35%). For thrombocytopenia and anemia, cumulative prevalence were 21.33%(95% CI :14.15%-30.84%)and 11.32%(95% CI :8.46%-14.98%) respectively. Moreover, cumulative prevalence of infection rate was33.52% (95% CI :28.99%-38.38%). Other adverse effect included tumor flare, deep vein thrombosis and fatigue. Conclusion: Lenalidomide is a considerable regimen for relapsed/refractory CLL patient.

Key words： Chronic lymphocytic leukemia Relapsed/Refractory Lenalidomide Adverse effect Meta-analysis

收稿日期: 2016-03-18

R969.3

通讯作者: 杨莉萍 E-mail: micky.mouse@163.com

引用本文:

梁良, 赵明, 朱愿超, 胡欣, 杨莉萍. 来那度胺治疗难治复发慢性淋巴细胞白血病疗效及不良反应的meta分析[J]. 临床药物治疗杂志, 2017, 15(1): 25-32.
LIANG Liang, ZHAO Ming, ZHU Yuan-chao , HU Xin, YANG Li-ping. Efficacy and adverse effect of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a meta-analysis. CLINICAL MEDICATION JOURNAL, 2017, 15(1): 25-32.

链接本文:

http://www.lcywzlzz.com/CN/doi:10.3969/j.issn.1672-3384.2017.01.005 或 http://www.lcywzlzz.com/CN/Y2017/V15/I1/25

[1] WHO.Chlymphocytic leukemia[EB/OL]. (2014-09-12)[2016-04- 21].www.who.int/selection_medicines/committees/expert/20/ applications/CLL.pdf?ua=1.
[2] Chen C I. Lenalidomide alone and in combination for chronic lymphocytic leukemia [J]. Current Hematologic Malignancy Reports, 2013, 8 (1): 7-13.
[3] Tam C S, O'Brien S, Plunkett W, et al. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab) [J]. Blood, 2014, 124 (20): 3059-3064.
[4] NCCN. Clinical Practice Guidelines in Oncology:Non- Hodgkin's lymphoma practice guidelines (EB/OL). (2015- 06-21)[ 2016-04-21] .https://www.nccn.org/store/login/login. aspx?ReturnURL=https://www.nccn.org/professionals/physician_ gls/pdf/nhl.pdf.
[5] Pollyea D A, Coutre S, Gore L, et al. A dose escalation study of ibrutinib with lenalidomide for relapsed and refractory chronic lymphocytic leukemia/small lymphocytic lymphoma [J]. Blood, 2014, 124 (21): 3059-3064.
[6] Yang Q, Modi P, Ramanathan S, et al. Idelalisib for the treatment of B-cell malignancies [J]. Expert Opin Orphan Drugs, 2015, 3 (1): 109-123.
[7] Zeldis J B, Knight R, Hussein M, et al. A review of the history, properties, and use of the immunomodulatory compound lenalidomide [J]. Ann N Y Acad Sci, 2011(1222): 76-82.
[8] Cortelezzi A, Sciume M , Reda G. Lenalidomide in the treatment of chronic lymphocytic leukemia [J]. Adv Hematol, 2012(2012): 393864.
[9] Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment [J]. Am J Hematol, 2015, 90 (5): 446-460.
[10] Team R C. R: a language and environment for statisticalcomputing. R Foundation for Statistical Computing[EB/OL]. (2013-3-23)[2016-04-21]. http://www.R-project.org/.
[11] Altman D G, Bland J M. Interaction revisited: the difference between two estimates [J]. BMJ, 2003, 326 (7382): 219.
[12] Messori A, Fadda V, Maratea D, et al. First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis [J]. Ann Hematol, 2015, 94 (6): 1003- 1009.
[13] Chanan-Khan A, Miller K C, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study [J]. J Clini Oncol, 2006, 24 (34): 5343-5349.
[14] Ferrajoli A, Lee B N, Schlette E J, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia [J]. Blood, 2008, 111 (11): 5291-5297.
[15] Ferrajoli A, Badoux X C, O'Brien S, et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) [J]. Blood, 2009, 114 (22): 89-90.
[16] K Maddocks, R. Lapalombella, K. A. Blum, et al. Preliminary results of a phase I study of lenalidomide in relapsed chronic lymphocytic leukemia [J]. Blood, 2009, 114 (22): 95-97.
[17] Witzig T E, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma [J]. J Clini Oncol, 2009, 27 (32): 5404-5409.
[18] Aue G, Soto S,Valdez J, et al. Phase II trial of pulse dosed lenalidomide in previously treated chronic lymphocytic leukemia [J]. Blood, 2010, 115 (21):116 .
[19] Badoux X, O'Brien S, Wierda W G, et al. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: Initial results of a phase II trial [J]. Blood, 2010, 115 (21):73-75.
[20] Costa L J, Fanning S, Stephenson J, et al. Phase 2 trial of intracycle sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia [J]. Clini Rev Allergy & Immunol, 2012, 13(3):189-200.
[21] Ferrajoli A, Falchi L, O'Brien S, et al. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL): Results of a phase II trial [J]. Blood, 2012, 120 (21): 69-72.
[22] Wendtner C M, Hillmen P, Mahadevan D, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia [J]. Leukemia Lymphoma, 2012, 53 (3): 417-423.
[23] Choi M Y, Castro J E, Hoff S, et al. Lenalidomide and rituximab for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia: Results of planned interim analysis [J]. Blood, 2013, 122 (21):52-66 .
[24] Badoux X C, Keating M J, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia [J]. J Clini Oncol, 2013, 31 (5): 584-591.
[25] Piris-Villaespesa M, Chavez J, Dalia S, et al. Updated results of a phase ii study of lenalidomide and rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia [J]. Haematologica, 2013(98): 46.
[26] Maffei R, Fiorcari S, Bulgarelli J, et al. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia [J]. Exp Hematol, 2014, 42 (2): 126-136.
[27] Maddocks K, Ruppert A S,Browning R, et al. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia [J]. Leuk Res, 2014, 38 (9): 1025-1029.
[28] Costa L J, Fanning S R, Stephenson J, et al. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma [J]. Leuk Lymphoma, 2015, 56 (3): 645-649.
[29] Wendtner C M, Hallek M,. Fraser G A, et al. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial [J]. Leuk Lymphoma, 2016, 57 (6): 1291-1299.
[30] Pinto A, Corazzelli G , De Filippi R. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response [J]. Cancer, 2012, 118 (6): 1738.
[31] Byrd J C, Furman R R, Coutre S E, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib [J]. Blood, 2015, 125 (16): 2497- 2506.
[32] Furman R R, Sharman J P, Coutre S E, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia [J]. N Engl J Med, 2014, 370 (11): 997-1007.
[33] Woyach J A , Johnson A J. Targeted therapies in CLL: mechanisms of resistance and strategies for management [J]. Blood, 2015, 126 (4): 471-477.